Compare Adaptive Biotechnologies Corp (ADPT) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares China Large-Cap ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while iShares China Large-Cap ETF trades at $33.49. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | FXI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $41.75 |
52-Week Low | $10.24 | $31.59 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
The iShares China Large-Cap ETF (FXI) trades at $32.51, up 1.88% on the day, while technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. Recent news highlights China's AI and chip sector driving factory rebounds and IPO activity, though broader sentiment on Chinese equities remains mixed, with some analysts labeling them as potential value traps. The ETF shows neutral oscillator readings with key support at $32 and resistance at $33.
The outlook for FXI is clouded by structural macroeconomic headwinds in China, including deflationary pressures and geopolitical tensions with the U.S., which offset potential opportunities from the country's massive AI infrastructure investment plans. While the sector benefits from technology self-reliance initiatives, persistent risks to corporate profitability and valuation compression suggest a cautious approach for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
